

# Jakob Schllhammer Knudsen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4202060/jakob-schollhammer-knudsen-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24  
papers

109  
citations

7  
h-index

10  
g-index

24  
ext. papers

186  
ext. citations

6.8  
avg, IF

2.92  
L-index

#	Paper	IF	Citations
24	Identifying Valid Algorithms for Number of Lines of Anti-Neoplastic Therapy in the Danish National Patient Registry Among Patients with Advanced Ovarian, Gastric, Renal Cell, Urothelial, and Non-Small Cell Lung Cancer Attending a Danish University Hospital.. <i>Clinical Epidemiology</i> , <b>2022</b> , 14, 159-171	5.9	
23	Changes in type 2 diabetes incidence and mortality associated with introduction of HbA1c as diagnostic option: A Danish 24-year population-based study.. <i>Lancet Regional Health - Europe, The</i> , <b>2022</b> , 14, 100291		1
22	Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e019356	6	4
21	A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population: A Danish nationwide cohort study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2354-2363	6.7	0
20	Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 520-529	6.7	7
19	Systemic lupus erythematosus during pregnancy is not associated with school performance in offspring - A Danish population-based study. <i>Lupus</i> , <b>2021</b> , 30, 228-237	2.6	0
18	Hospitalization for hypoglycaemia in people with diabetes in Denmark, 1997-2017: Time trends in incidence and HbA and glucose-lowering drug use before and after hypoglycaemia. <i>Endocrinology, Diabetes and Metabolism</i> , <b>2021</b> , 4, e00227	2.7	
17	Nationwide Trends in Cardiac Risk and Mortality in Patients With Incident Type 2 Diabetes: A Danish Cohort Study. <i>Diabetes Care</i> , <b>2021</b> ,	14.6	1
16	Development and validation of a model for predicting mortality in patients with hip fracture.. <i>Age and Ageing</i> , <b>2021</b> ,	3	1
15	Trends in HbA and LDL Cholesterol in Patients With Type 2 Diabetes Receiving First-Time Treatment in Northern Denmark, 2000-2017: Population-Based Sequential Cross-Sectional Analysis. <i>Diabetes Care</i> , <b>2020</b> , 43, e17-e19	14.6	6
14	Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study. <i>PLoS ONE</i> , <b>2020</b> , 15, e0229621	3.7	16
13	Differences Between Randomized Clinical Trial Participants and Real-World Empagliflozin Users and the Changes in Their Glycated Hemoglobin Levels. <i>JAMA Network Open</i> , <b>2020</b> , 3, e1920949	10.4	8
12	Acute pancreatitis: 31-Year trends in incidence and mortality - A Danish population-based cohort study. <i>Pancreatology</i> , <b>2020</b> , 20, 1332-1339	3.8	7
11	Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study <b>2020</b> , 15, e0229621		
10	Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study <b>2020</b> , 15, e0229621		
9	Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study <b>2020</b> , 15, e0229621		
8	Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study <b>2020</b> , 15, e0229621		

7	Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study <b>2020</b> , 15, e0229621		
6	Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study <b>2020</b> , 15, e0229621		
5	Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study. <i>Journal of Diabetes</i> , <b>2019</b> , 11, 690-694	3.8	3
4	Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails. <i>Sexual Medicine Reviews</i> , <b>2019</b> , 7, 430-441	5.6	13
3	Different mechanisms involved in liraglutide and glucagon-like peptide-1 vasodilatation in rat mesenteric small arteries. <i>British Journal of Pharmacology</i> , <b>2019</b> , 176, 386-399	8.6	9
2	Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide. <i>Diabetes Care</i> , <b>2018</b> , 41, e133-e135	14.6	12
1	Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats. <i>British Journal of Pharmacology</i> , <b>2017</b> , 174, 2563-2575	8.6	21